1
项与 CD19/BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology ) 相关的临床试验Sequential Infusion of CD19 and BCMA Chimeric Antigen Receptor T Cells to Improve Alloimmune-mediated Platelet Transfusion Refractoriness in Patients With Acute Leukemia in Complete Remission
Alloimmune-mediated platelet transfusion refractoriness(PTR) was usually caused by repeated blood transfusions and pregnancy and accounts for about 20-25% of PTR patients. Patients with acute leukemia need repeated platelet infusion in myelosuppression period after chemotherapy, and PTR incidence is more higher.PTR was associated with adverse events,including longer hospital stays,severe hemorrhages and an increased risk of early deaths and may have a negative impact on the success of HSCT. The current management of patients with PTR includes specific transfusion strategies, IVIG, rituximab,thrombopoietin-receptor agonists(TPO-RA) ,bortezomib or splenectomy,have been largely unsatisfactory. As we know, HLA antibodies are mainly secreted by the plasma cells. Researchers want to see if sequential infusion of CD19 and BCMA CAR-T cells can clear the B cells and plasma cells, can help increase platelet levels and reduce bleeding in patients with platelet transfusion refractoriness. To see if sequential infusion can increases platelet levels more after a transfusion. To see if it reduces the chance of bleeding. Adults 16-65 years old who diagnosed with acute leukemia in CR and alloimmune platelet transfusion refractoriness.
100 项与 CD19/BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology ) 相关的临床结果
100 项与 CD19/BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology ) 相关的转化医学
100 项与 CD19/BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology ) 相关的专利(医药)
100 项与 CD19/BCMA CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology ) 相关的药物交易